Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime
March 06, 2023 08:00 ET
|
Windtree Therapeutics
US Hospital Claims Data Reveals Cardiogenic Shock Patients Have an Average Hospital Length of Stay of 19.6 Days Making Its Intensive Patient Care Cost Very High WARRINGTON, Pa., March 06, 2023 ...
Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure
February 28, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage...
Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference
February 27, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
February 24, 2023 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage...
Windtree Therapeutics Announces Reverse Stock Split
February 23, 2023 12:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing multiple late-stage...
Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants
January 20, 2023 08:37 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has entered into warrant inducement offer letters (the...
Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance
December 05, 2022 07:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage...
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates
November 14, 2022 07:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular...
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent
October 25, 2022 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure
September 28, 2022 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...